Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Eribulin mesylate|DRUG: Eribulin mesylate|DRUG: Eribulin mesylate|OTHER: Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|OTHER: Biologic: PEGylated recombinant human hyaluronidase
Sponsor: Eisai Inc.
Collaborators: Halozyme Therapeutics